Elected to the Board 2005
Born: 1966
Education: Stockholm School of Economics.
Previous assignments: Co-founder of Bactiguard and CEO 2005-2014 and 2015-2020. Chairperson of the Board 2014-2015 and 2023. Founder and CEO of Kinchard AB and Netpharma AB.
Other current assignments (select): Co-founder and Chairperson of the Board of SmartCella Holding AB. Owner and Board member of GIDL Invest AB. Board member of Swecare AB.
Shareholdings: 2,000,000 A shares via companies and 4,179,426 B shares through family, personal holdings.
Elected to the Board 2019
Born: 1966
Education: BSc Business and Economics, Stockholm School of Economics.
Background: Co-founder of Bactiguard and Chairman of the Board 2005-2013. CEO of EQT.
Other assignments: Deputy Managing Partner in EQT Partners AB, EQT Partners AB, Board member Kochcompany AB and TomEnterprise AB.
Shareholdings: 2,000,000 A-shares, 4,604,182 B-shares and 1,142,436 B-shares via a capital insurance with a company, controlled by Thomas von Koch, as beneficiary
Elected to the Board 2019
Born: 1969
Education: MD, Ph.D, Karolinska Institutet, Board Certified Surgeon
Previous assignments: Dean Campus North, Karolinska Institutet, Member of the Faculty Board and Board of Research at Karolinska Institutet.
Other current assignments (select): Professor of Surgery, Karolinska Institutet, Senior Consultant Surgeon, Karolinska University Hospital, Scientific Director Life Science, Karolinska Institutet. Board member of Radiumhemmets Forskningsfonder, Research!Sweden and Genomic Medicine Sweden.
Shareholdings: 2,600 B-shares as personal holdings and 28,818 call options.
Independent in relation to the Company and its management and the Company’s major shareholders.
Elected to the Board 2018
Born: 1962
Education: BSc Business and Economics, Stockholm School of Economics. Studies at the MBA programme at New York University, Stern School of Business.
Previous assignments: Partner, Deputy CEO and Deputy Chairperson of private equity firm EQT
Other assignments: Board member of Trelleborg AB and ITB-Med AB. Founder and CEO of Trill Impact AB.
Shareholdings: 3,605,150 B shares as personal holdings
Elected to the board 2022
Born: 1971
Education: Master’s degree in international economics and licentiate degree in industrial economics from Linköping University.
Previous assignments: Former CEO of Interflora and SamSari, as well as several roles within Microsoft and WM Data. Digitization as a core competence.
Other assignments: Chairperson of the Board of SK Shieldus (South Korea), board member of NCAB Group, Recover Nordic Group and Qarlbo AB, as well as advisor to private equity firm EQT. Former Chairperson of the Board of Affecto Plc, Nexon Asia Pacific and Iver Holding AB.
Shareholdings: 28,818 call options
Independent in relation to the Company and its management and the Company’s major shareholders.
Elected to the Board 2023
Born: 1957
Education: Studies at Miami University and medical degree from Case Western Reserve University School of Medicine. Residency/chief residency in internal medicine at the University of Texas Southwestern Medical School, Parkland Hospital. Fellowships in cardiovascular diseases and interventional cardiology at Harvard Medical School and the Beth Israel Hospital. Master of Science in Biostatistics from the Harvard T.H. Chan School of Public Health.
Previous assignments: Chief Medical Officer & Scientific Officer at Medtronic PLC (NYSE:MDT). Founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston. Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Clinical Biometrics, and as an Interventional Cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston.
Founding Governor of the Patient Centered Outcomes Research Institute (PCORI), as part of the US Affordable Care Act. Presently a working group member of NIH’s Helping to End Addiction Long-term® (HEAL) program.
Other assignments: Board member of ZimVie Inc., Identiv Inc., and Cognito Therapeutics, Inc.
Shareholdings: 121,655 call options.
Independent in relation to the Company and its management and the Company’s major shareholders.